Author(s): Olczak A, Grabczewska E, Olczak A, Grabczewska E
Abstract Share this page
Abstract The pre-exposure chemoprophylaxis (PrEP) is an experimental approach to HIV prevention. The use of antiretroviral drugs has been shown to be effective in prevention HSIV infection in animals. The results from ongoing clinical PrEP trials have demonstrated that antiretrovirals were able to reduce HIV incidence in women and men. The CAPRISA-004 study demonstrated that 1\% TDF gel applied intravaginally decreased the risk of HIV infection among heterosexual women in South Africa. The largest global trial iPr Ex conducted in men who have sex with men (MSM), has demonstrated that chemoprophylaxis with daily oral TDF/FTC was 44\% effective in protecting against HIV transmission. Following the results of the iPrEx study, the US CDC issued the interim guidance regarding the use of oral PrEP among MSM. Currently more then 20.000 people will be enrolled in studies with oral or topical antiretroviral agents as pre-exposure chemoprophylaxis.
This article was published in Przegl Epidemiol
and referenced in Journal of AIDS & Clinical Research